中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

87 records (took 0.038 seconds)

    Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
    72.
    发明申请
    Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones 失效
    羟基烷基取代的吡啶-7-基嘧啶-7-酮

    公开(公告)号：US20080119497A1

    公开(公告)日：2008-05-22

    申请号：US11985821

    申请日：2007-11-19

    Applicant: David Goldstein

    Inventor： David Goldstein

    IPC: A61K31/519 ,  C07D487/02 ,  A61P19/02

    CPC classification number: C07D471/04

    Abstract: Compounds of the Formula: where X1, Ar1, R1, and R2 are as defined herein, and compositions comprising the same. Also provided are methods for using compounds of Formula I in treating p38 mediated disorders in a patient.

    Abstract translation: 其中X 1，Ar 1，R 1和R 2的化合物如本文所定义 ，及其组合物。 还提供了使用式I化合物治疗患者中p38介导的病症的方法。

    Methods of inhibiting BTK and SYK protein kinases
    73.
    发明申请
    Methods of inhibiting BTK and SYK protein kinases 失效
    抑制BTK和SYK蛋白激酶的方法

    公开(公告)号：US20070219195A1

    公开(公告)日：2007-09-20

    申请号：US11725752

    申请日：2007-03-20

    Applicant: David Goldstein ,  Matthias Rueth

    Inventor： David Goldstein ,  Matthias Rueth

    IPC: A61K31/5377 ,  A61K31/502

    CPC classification number: A61K31/502 ,  A61K31/5377

    Abstract: Methods of inhibiting a tyrosine kinase wherein said tyrosine kinase is BTK or SYK comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula I are disclosed. The compounds are useful for treating auto-immune and inflammatory diseases.

    Abstract translation: 抑制酪氨酸激酶的方法，其中所述酪氨酸激酶是BTK或SYK，包括向有需要的患者施用治疗有效量的式I化合物。 该化合物可用于治疗自身免疫和炎性疾病。

    6-alkoxy-pyrido-pyrimidines
    75.
    发明申请
    6-alkoxy-pyrido-pyrimidines 失效
    6-烷氧基 - 吡啶并 - 嘧啶

    公开(公告)号：US20060276646A1

    公开(公告)日：2006-12-07

    申请号：US11503697

    申请日：2006-08-14

    Applicant: David Goldstein ,  Julie Lim

    Inventor： David Goldstein ,  Julie Lim

    IPC: C07D471/02 ,  C07D487/02

    CPC classification number: C07D471/04

    Abstract: The present invention provides compounds of the Formula I: wherein R1 is alkyl, cycloalkyl, cycloallkylalkyl, or —CH2-alkenyl, X1 is O, NH, N(alkyl), S or —C(═O), Z is N or CH; and R2 and R3 are as defined herein, pharmaceutical compositions comprising same, and methods for their use.

    Abstract translation: 本发明提供了式I的化合物：其中R 1是烷基，环烷基，环烷基烷基或-CH 2 - 烯基，X 1， 是O，NH，N（烷基），S或-C（-O），Z是N或CH; R 2和R 3如本文所定义，包含其的药物组合物及其使用方法。

    Decision support method and system
    77.
    发明申请
    Decision support method and system 审中-公开
    决策支持方法和系统

    公开(公告)号：US20060235707A1

    公开(公告)日：2006-10-19

    申请号：US11108725

    申请日：2005-04-19

    Applicant: David Goldstein ,  Darryl Busch

    Inventor： David Goldstein ,  Darryl Busch

    IPC: G06Q99/00

    CPC classification number: G05B23/0283 ,  F42B15/00 ,  F42B35/00 ,  G06Q30/0278

    Abstract: In accordance with the invention, there is a decision support method comprising collecting data about a set of components of an asset, wherein the data comprises information about the status of each component in the set of components. The method also comprises comparing the data to a set of requirements for a use of the asset and estimating a remaining life for each of the components in the set of components based on the status of each of the components and the set of requirements for an intended use of the asset.

    Abstract translation: 根据本发明，存在一种决策支持方法，包括收集关于资产的一组组件的数据，其中所述数据包括关于所述组件集合中的每个组件的状态的信息。 该方法还包括将数据与用于使用资产的一组要求进行比较，并且基于每个组件的状态以及针对预期的组合的要求估计组件组中的每个组件的剩余寿命 使用资产。

    Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
    78.
    发明申请
    Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor 审中-公开
    用干扰素α和表皮生长因子受体激酶抑制剂联合治疗

    公开(公告)号：US20060134064A1

    公开(公告)日：2006-06-22

    申请号：US11303728

    申请日：2005-12-16

    Applicant: David Goldstein ,  Xian-Jun Qu ,  Pamela Russell ,  Jia-Lin Yang

    Inventor： David Goldstein ,  Xian-Jun Qu ,  Pamela Russell ,  Jia-Lin Yang

    IPC: A61K38/21 ,  A61K31/175 ,  A61K31/7048

    CPC classification number: A61K31/175 ,  A61K31/7048 ,  A61K38/212 ,  A61K2300/00

    Abstract: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and IFNα combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and IFNα combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEVA®).

    Abstract translation: 本发明提供了一种用于治疗患者的肿瘤或肿瘤转移的方法，其包括向所述患者同时或依次施用治疗有效量的EGFR激酶抑制剂和IFNα组合，所述另外的药物或治疗剂， 癌症药物或放射治疗。 本发明还包括药物组合物，其由EGFR激酶抑制剂和IFNalpha组合与药学上可接受的载体组合组成。 可用于实施本发明的EGFR激酶抑制剂的优选实例是化合物厄洛替尼HCl（也称为TARCEVA）。

Patent Agency Ranking